Augmedix, Inc. provided earnings guidance for the third quarter ended September 30, 2021. For the quarter, the company's total revenue is expected to increase approximately 9% over the second quarter of 2021. Revenue grew approximately 33% in the third quarter of 2021 compared to the third quarter of 2020. Preliminary Net Loss for the third quarter of 2021 is expected to be in the range of $2.8 million to $3.2 million.